Bria Carley, Wegner Rodney E, Clump David A, Vargo John A, Mintz Arlan H, Heron Dwight E, Burton Steven A
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
J Cancer Res Ther. 2011 Jan-Mar;7(1):52-7. doi: 10.4103/0973-1482.80462.
Although the vast majority of meningiomas are not malignant, their location within the cranial vault often leads to the development of symptoms. Traditional therapy has included observation, surgical resection, radiation therapy or a multimodality approach. The objective of this study is to review the outcomes in patients with meningioma treated at our institution using stereotactic radiosurgery.
A total of 73 patients (median age of 59, 15 male and 58 female) with meningioma (median volume of 5.54 cc) underwent Cyber Knife TM stereotactic radiosurgery at our institution. Sixty patients had WHO grade 1 meningioma, eleven patients had WHO grade 2 meningioma, and two patients had WHO grade 3 meningioma. Treatment consisted of a median dose of 17.5 Gy (range, 6 - 27 Gy) delivered over a median of three fractions (range: 1 - 5). The patients were followed by clinical examination as well as serial imaging with magnetic resonance imaging (MRI).
The median follow-up was 16.1 months (range, 1.5 - 98.0). Follow-up MRI was available in all 73 patients. Local failure was documented in 11 cases. Actuarial local control at one year was 95, 71, and 0% for WHO grade 1, WHO grade 2, and WHO grade 3, respectively. There was no acute grade 3 or greater toxicity and only one episode of late grade 3 toxicity. A subjective improvement in the existing, tumor-related symptoms was noted in 60% of the patients.
Stereotactic radiosurgery is a safe and effective treatment for meningioma. Tumor-related symptoms often improve after treatment.
尽管绝大多数脑膜瘤并非恶性,但其位于颅腔内的位置常常导致症状的出现。传统治疗方法包括观察、手术切除、放射治疗或多模式治疗。本研究的目的是回顾在我们机构接受立体定向放射外科治疗的脑膜瘤患者的治疗结果。
共有73例脑膜瘤患者(中位年龄59岁,男性15例,女性58例)(中位体积5.54立方厘米)在我们机构接受了射波刀立体定向放射外科治疗。60例患者为世界卫生组织(WHO)1级脑膜瘤,11例为WHO 2级脑膜瘤,2例为WHO 3级脑膜瘤。治疗的中位剂量为17.5 Gy(范围6 - 27 Gy),分中位3次给予(范围:1 - 5次)。对患者进行临床检查以及磁共振成像(MRI)序列成像随访。
中位随访时间为16.1个月(范围1.5 - 98.0个月)。所有73例患者均有随访MRI。记录到11例局部复发。WHO 1级、WHO 2级和WHO 3级脑膜瘤患者1年时的精算局部控制率分别为95%、71%和0%。没有发生3级或更高级别的急性毒性反应,仅发生1次3级晚期毒性反应。60%的患者肿瘤相关症状有主观改善。
立体定向放射外科是治疗脑膜瘤的一种安全有效的方法。治疗后肿瘤相关症状常有所改善。